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Abstract 
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance 
inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form 
of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a 
down-stream effect of AR activity is a promising rationale for management of this disease. The humanized 
IgG1 antibody hu11B6 internalizes into prostate and prostate cancer (PCa) cells by binding to the catalytic 
cleft of human kallikrein 2 (hK2), a prostate specific enzyme governed by the AR-pathway. In a previous 
study, hu11B6 conjugated with Actinium-225 (225Ac), a high linear energy transfer (LET) radionuclide, was 
shown to generate an AR-upregulation driven feed-forward mechanism that is believed to enhance 
therapeutic efficacy. We assessed the efficacy of hu11B6 labeled with a low LET beta-emitter, 
Lutetium-177 (177Lu) and investigated whether similar tumor killing and AR-enhancement is produced. 
Moreover, single-photon emission computed tomography (SPECT) imaging of 177Lu is quantitatively 
accurate and can be used to perform treatment planning. [177Lu]hu11B6 therefore has significant potential 
as a theranostic agent. 
Materials and Methods: Subcutaneous PCa xenografts (LNCaP s.c.) were grown in male mice. 
Biokinetics at 4-336 h post injection and uptake as a function of the amount of hu11B6 injected at 72 h 
were studied. Over a 30 to 120-day treatment period the therapeutic efficacy of different activities of 
[177Lu]hu11B6 were assessed by volumetric tumor measurements, blood cell counts, molecular analysis 
of the tumor as well as SPECT/CT imaging. Organ specific mean absorbed doses were calculated, using a 
MIRD-scheme, based on biokinetic data and rodent specific S-factors from a modified MOBY phantom. 
Tumor tissues of treated xenografts were immunohistochemically (IHC) stained for Ki-67 (proliferation) 
and AR, SA-β-gal activity (senescence) and analyzed by digital autoradiography (DAR). 
Results: Organ-to-blood and tumor-to-blood ratios were independent of hu11B6 specific activity except 
for the highest amount of antibody (150 µg). Tumor accumulation of [177Lu]hu11B6 peaked at 168 h with 
a specific uptake of 29 ± 9.1 percent injected activity per gram (%IA/g) and low accumulation in normal 
organs except in the submandibular gland (15 ± 4.5 %IA/g), attributed to a cross-reaction with mice 
kallikreins in this organ, was seen. However, SPECT imaging with therapeutic amounts of [177Lu]hu11B6 
revealed no peak in tumor accumulation at 7 d, probably due to cellular retention of 177Lu and decreasing 
tumor volumes. For [177Lu]hu11B6 treated mice, tumor decrements of up to 4/5 of the initial tumor 
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volume and reversible myelotoxicity with a nadir at 12 d were observed after a single injection. Tumor 
volume reduction correlated with injected activity and the absorbed dose. IHC revealed retained 
expression of AR throughout treatment and that Ki-67 staining reached a nadir at 9-14 d which coincided 
with high SA- β-gal activity (14 d). Quantification of nuclei staining showed that Ki-67 expression 
correlated negatively with activity uptake. AR expression levels in cells surviving therapy compared to 
previous timepoints and to controls at 30 d were significantly increased (p = 0.017).  
Conclusions: This study shows that hu11B6 labeled with the low LET beta-emitting radionuclide 177Lu 
can deliver therapeutic absorbed doses to prostate cancer xenografts with transient hematological 
side-effects. The tumor response correlated with the absorbed dose both on a macro and a small scale 
dosimetric level. Analysis of AR staining showed that AR protein levels increased late in the study 
suggesting a therapeutic mechanism, a feed forward mechanism coupled to AR driven response to DNA 
damage or clonal lineage selection, similar to that reported in high LET alpha-particle therapy using 225Ac 
labeled hu11B6, however emerging at a later timepoint. 
 
Introduction 
Castration resistant prostate cancer (CRPC) is 
associated with poor prognosis and is often 
characterized by sustained AR-signaling over the 
entire course of disease progression. In fact, 
‘castrate-resistant’ reflects continued androgen 
dependence, rather than independence [1]. Thus, 
much of the effort spent developing new 
pharmacological compounds has been focused on 
either AR blockade or androgen synthesis deprivation 
with drugs such as apalutamide and abiraterone. 
However, despite interventions with these drugs (and 
often following an initial response), some form of 
reactivation of the AR pathway inevitably occurs. The 
radiotherapeutic we consider here follows an 
alternate line of reasoning. Rather than attempting to 
disrupt the AR-signaling, we take advantage of its 
presence by targeting potent cytotoxic agents to 
proteins resultant from AR pathway activation [2].  
The use of radioimmunotherapy (RIT) has been 
shown to be a successful treatment of liquid tumors 
using anti-CD20 and CD33 antibodies [2,3]. 
Radionuclide therapy of CRPC patients using prostate 
specific membrane antigen (PSMA) targeting 
modalities are promising but might have severe 
dose-limitations due to high expression and uptake in 
off-target organs such as salivary glands and kidneys 
[4-7]. 
Human kallikrein related peptidase 2 (hK2) is a 
serine protease that is exclusively found in prostate 
tissues (both healthy and malignantly derived) and is 
known to have increased expression with the severity 
of the disease [8-11]. KLK2, the gene encoding hK2, is 
regulated by the AR pathway. In a manner similar to 
that of the closely related kallikrein, Prostate specific 
antigen (PSA), active hK2 is retrograde released into 
the blood where it is immediately deactivated by 
abundant protease inhibitors [12]. We have devised a 
humanized targeting platform based on the 
construction of an antibody, hu11B6, which is specific 
for the catalytic cleft of active hK2. To date, we have 
shown that hu11B6 specifically internalizes into hK2 
expressing cells in vivo through a mechanism that 
relies on the intact variable region, and on the 
fragment crystallizable (Fc) region’s ability to bind to 
the neonatal Fc receptor (FcRn) [13].  
In a previous study, following therapy with 
hu11B6 labeled with the high LET alpha-particle 
emitting radionuclide Actinium-225 (225Ac), we 
reported an increase in AR-activity and hK2 
production in cells as an effect of DNA repair [14]. 
The AR flair phenomenon has initially been reported 
based on Caesium-137 (137Cs) external beam radiation 
[15, 16], and to our knowledge it has not been 
previously demonstrated that low LET beta-emissions 
generate the same effect. High LET alpha-particles 
produce irreparable damage, i.e. DNA double strand 
breaks (DSB), when traversing the nucleus compared 
to low LET beta-particles which to a higher degree 
indirectly damage the cell via the creation of reactive 
oxygen species [17,18]. This oxidative stress results in 
DNA single strand breaks (SSB) and a lower 
frequency of DSB. However, the occurrence of an AR 
flair phenomenon caused by low LET beta-particles 
could potentially result in enhanced treatment 
efficacies relating to a feed-forward mechanism. This 
is of particular interest since various low LET 
β-emitters are frequently used in radiotherapeutic 
agents.  
The overarching aim of the current study was to 
gather dosimetric, therapeutic and radiobiological 
data that will guide our upcoming clinical translation 
of radiolabeled hu11B6. In this study we investigated 
whole body and small-scale tumor dosimetry in an 
animal model, as well as therapeutic and biological 
effects of hu11B6 labeled with Lutetium-177 (177Lu), a 
low LET beta-emitter with significant interest for 
theranostic clinical RIT.  
 Theranostics 2019, Vol. 9, Issue 8 
 
 
http://www.thno.org 
2131 
Materials and methods 
Conjugation, radiolabeling and affinity 
measurements of hu11B6 
Conjugation, radiolabeling and stability studies 
were performed as previously described [18]. In 
summary, hu11B6 and non-specific isotype control 
IgG1 were conjugated with p-SCN-Bn-CHX-A”-DTPA 
(Macrocyclics, Dallas, TX), a backbone substituted 
diethylenetriaminepentaacetic acid (DTPA) derivate 
chosen as a trade-off between stability and metal ion 
complexation [19], in a 1:3 molar ratio. 50 – 250 MBq 
177LuCl3 (IDB Petten BV, Baarle-Nassau, Holland) was 
added to 150 µg of hu11B6 (~1 µg/µL) in ammonium 
acetate buffer (pH of ~5.5), with a final volume of 500 
µL. After 2 h of incubation, free 177Lu was eluted from 
177Lu-DTPA-hu11B6 ([177Lu]hu11B6) and 
177Lu-DTPA-IgG1 ([177Lu]IgG1) using a NAP-5 column 
(GE Healthcare, Uppsala, Sweden) equilibrated with 
saline or PBS. Stability of [177Lu]hu11B6 was studied 
by incubating samples (n = 3) in mouse serum at 37°C 
for 1 w, using labeled conjugate in PBS as a control. 
Separation was performed on NuPAGE®Bis-Tris Gel 
(Life technologies via Thermo Fischer Scientific). The 
conjugation and radiolabeling of the non-specific 
antibody, an IgG antibody from mouse serum (Sigma, 
I-8765), was performed as above. Binding affinity of 
177Lu-hu11B6 was evaluated and compared to 
non-labeled hu11B6 using Surface Plasmon 
Resonance (SPR), see suppl. information.  
Cell line  
LNCaP-FGC was purchased from American 
Type Culture Collection (ATCC, Manassas, VA) and 
cultured according to their instructions.  
Animal model  
All animal experiments were performed in 
accordance with the regional Ethics Committee's 
requirements. Male BALB/c foxn1nu/foxn1nu (in 
house) or NMRI foxn1nu/foxn1nu (Charles River 
Laboratories, Wilmington, MA) were inoculated 
subcutaneously in the right flank with the KLK2 
expressing cell line LNCaP-FGC in a suspension of 1:1 
mixture of RPMI-1640 media and Matrigel (BD 
Biosciences, San Jose, CA). Due to the technical 
difficulties of sampling enough blood related to the 
size of BALB/c foxn1nu/foxn1nu mice, the relatively 
larger NMRI nude mice were added to obtain a 
complete picture of the blood status but not included 
in the survival analysis. 
Specific activity and biodistribution study 
Mice bearing LNCaP s.c. xenografts (n = 3 - 4 per 
group) were administered fixed activities of 
[177Lu]hu11B6 by tail-vein injections (0.4 - 0.6 MBq). 
The mass amounts of hu11B6 injected were however 
varied; 10, 30, 50, 100, 150 µg. Tumors, blood, and 
organs were collected at 72 h post-injection. A 
separate set of mice bearing LNCaP s.c. xenografts 
was administered with a roughly fixed specific 
activity of [177Lu]hu11B6 (20 - 30 µg of protein and 0.4 
- 0.6 MBq of 177Lu) but in this case tumors, blood, and 
organs were collected at 4, 24, 48, 72, 168 and 336 h 
post-injection. Animals were euthanized using 
intra-peritoneal injections of Ketalar-Rompun (10 
µL/g, bodyweight), or via carbon dioxide inhalation, 
followed by heart puncture and collection of blood. 
Harvested tissues were weighed and measured in a 
NaI(Tl) well counter (1480 Wizard, Wallac, Perkin 
Elmer) and compared to radioactive standards. The 
count data were background and decay corrected, and 
uptake was expressed as percent injected activity per 
gram of tissue (%IA/g).  
SPECT/CT 
A preclinical SPECT/CT scanner (NanoSPECT/ 
CT Plus, Mediso; Budapest, Hungary) equipped with 
the NSP-106 multipinhole mouse collimator was used 
and with energy windows of 20% centered over the 
56-, 113-, and 208-keV energy peaks of 177Lu. 
Acquisition time was about 40 min. Mice given 
therapeutic amounts of [177Lu]hu11B6 and dedicated 
for molecular tumor analysis (see section on 
therapeutic efficacy) were imaged at 4, 7, 9 and 14 d (n 
= 4) post injection. CT imaging was done before each 
whole-body SPECT. SPECT data was reconstructed 
using HiSPECT software (SciVis; Goettingen, 
Germany). With the help of the CT images as an 
anatomical reference, regions of interest (ROI), where 
drawn for tumor, submandibular glands, liver and 
heart using the VivoQuant 3.0 software (inviCRO; 
Boston, MA). Activity data (MBq/mm3) was extracted 
and then converted to percent injected activity per 
gram of tissue (%IA/g) by assuming a tissue density 
of 1.0 g/cm3.  
Therapeutic efficacy 
LNCaP tumor bearing mice (tumor > 3mm in 
diameter) were randomized to one of seven groups, 
with one group randomized for molecular tumor 
analysis using pre-set euthanization time-points at 4, 
9, 14 and 30 d after initiation of treatment and with 
one group left untreated. All mice were administered 
a single injection having a protein mass of 30 µg, 
determined based on previous results [20] and on the 
results of the aforementioned specific activity study. 
Syringe activity (MBq) was measured before and after 
injection (Atom Lab 500 Dose Calibrator, Biodex 
Medical Systems Inc., Shirley, NY) to determine the 
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range of individually injected activity (Table 1). 
Bodyweight and tumor volume (external caliper 
measurement, V = 0.5 × length × width × width) were 
monitored 2–3 times per week up to 120 d post 
injection. For tumor size range at start of therapy, see 
the Supplementary Information section. Relative 
tumor size (RTS) was calculated as the natural 
logarithm of the fractional increase in volume relative 
to the tumor size at treatment start [21]. Tumor 
diameter >15 mm, or severe decline in general 
condition, were used as endpoints. The total white 
blood cell counts (WBC), red blood cell counts (RBC) 
and platelets (PLT) were measured twice weekly 
during the first month. Blood samples (20 µL) were 
collected from the tail vein and analyzed in an Exigo 
Veterinary (Exigo Vet) Hematology Analyzer (Boule 
Medical, Stockholm, Sweden).  
Immunohistochemistry and androgen 
receptor intensity analysis 
After mice were euthanized, tumor tissue was 
collected, portioned and cryo-preserved in optimal 
cut temperature cryomount (Histolab Products AB, 
Stockholm, Sweden), or first fixed in 4% 
paraformaldehyde (PFA) solution and embedded in 
paraffin before sectioning. Prior to staining for Ki-67 
and AR, cryosections were dried for 15 min in 37°C 
and then fixed with 4% PFA and quenched for 5-10 
min using Dako REAL Peroxidase blocking solution 
(Agilent Technologies, Santa Clara, Ca, US), then 
incubated with rabbit anti-Ki-67 mAb (Clone SP6, 
Thermo Fischer Scientific) or anti-AR mAb (ab133273, 
Abcam, Cambridge, UK) respectively, followed by a 1 
h incubation with horseradish peroxidase conjugated 
Goat anti-rabbit F(ab)2 (111-036-045, Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA) 
and developed with Dako liquid DAB+ 
substrate-chromogen system (Agilent Technologies). 
For detection of SA-β-gal activity, a marker of 
senescence, the Abcam senescence detection kit 
(ab65351) was used on cryosections first dried for 15 
min in 37°C and then fixed in 1% formalin for 1 min 
(fixative solution from kit). After counterstaining with 
hematoxylin, or in the case of SA-β-gal activity, with 
nuclear fast red solution (Sigma-Aldrich, Saint Louis, 
Mo) and mounting with Pertex (Histolab), the sections 
were imaged using a MIRAX MIDI automated whole 
slide imager (Carl Zeiss AG, Oberkochen, Germany). 
The Ki-67, AR and SA-β-gal stained sections were 
independently evaluated by two skilled observers and 
graded from no visible staining (-) to the most intense 
staining (+++). 
Sections from paraffin embedded blocks were 
also used together with a modified AR staining 
protocol where the concentration of anti-AR mAb was 
eight times lower than previously. This resulted in 
tissue section images with a range of AR expression 
intensities (as opposed to the effectively binary 
staining achieved when high concentration of anti-AR 
mAb was applied). These sections were analyzed as 
follows. Masks selecting the AR expressing cells 
within the images were generated using the Color 
Threshold, Make Binary and Analyze Particle 
functions within ImageJ [22]. These masks were then 
applied to the original images (in RGB format) and 
inverted mean-cell-intensities were calculated using 
code written in Matlab (MATLAB and Statistics 
Toolbox Release 2012b, The MathWorks, Inc., Natick, 
Massachusetts, United States). 
Macro- and small-scale dosimetry  
Mean absorbed dose was calculated using a 
previously described MIRD-scheme with 
mouse-specific S-factors [20, 23]. For calculation of 
organ/tumor S-factors relevant for the used animal 
model, a version of the MOBY phantom [24] was 
applied. Actual organ sizes were used as input for the 
S-value calculations using the Monte Carlo package 
MCNP6. Bi-exponential curves were fitted to the 
biokinetic data by least-square-fit to calculate the 
time-integrated activity coefficient (see suppl. 
information). The absorbed dose to the bone marrow 
was calculated based on the assumption that the 
activity concentration in red marrow is proportional 
to blood at a ratio of 0.36 [25]. 
DAR of xenograft cryosections was performed 
using a Biomolex 700 Imager (Biomolex AS, Oslo, 
Norway) having an intrinsic spatial resolution of 50 
µm and a 177Lu detection efficiency as previously 
reported [26]. Corrections were applied for dead or 
miscalibrated detector strips and radioactive decay. 
To scale to specific uptake, each pixel was assumed to 
contain a tissue volume of 50x50x8 µm3 and have a 
density of 1.0 g/cm3. Autoradiographic images were 
analyzed using IDL 8.5 (Exelis VIS, Harris 
Corporation) and ImageJ. The absorbed-dose rate 
distribution was calculated using a dose point kernel 
(DPK) acquired by Monte Carlo simulation [27]. All 
layers along one axis of the three-dimensional DPK 
were summed to form a two-dimensional DPK that 
includes contributions from assumed identical 
activity distributions above and below the imaged 
sections. The image resolution was then 
down-sampled to 100 µm pixels to match the DPK 
before convolution was performed to produce 
absorbed-dose rate images. Correlation between 
specific uptake or absorbed dose rate and cell 
proliferation was evaluated by comparing three to six 
ROIs, each about 1.3 ± 1.1 mm2, drawn using ImageJ 
on each image along with an identical ROI in the 
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adjacent Ki-67 stained slide [28]. The intensity of 
staining per nuclear area in these images was 
determined using the ImageJ Immunoratio plugin [29] 
with the threshold set to the maximum level to avoid 
false positive classification of hemochromatic areas as 
an effect of the RIT. Correlation was tested with the 
non-parametric Spearman correlation measure using 
IBM SPSS Statistics version 23.  
Statistical and Image Analysis 
Data are presented as the mean ±SD and 
statistical significance was analyzed using the t-test, 
unless otherwise noted. In all cases, differences in 
results were taken to be statistically significant with 
computed p < 0.05. Linear regression was applied to 
evaluate treatment and dose response. Median 
survival was calculated from Kaplan Meier graphs 
generated with Prism 4. Statistical analyses were 
performed using GraphPad Prism version 4 
(GraphPad Software Inc., San Diego, CA), IBM SPSS 
Statistics version 23 (SPSS Inc., Chicago, IL) and Excel 
2016 (Microsoft). 
Results 
Conjugation, Radiolabeling, Stability and 
Affinity 
The labeling yield for [177Lu]hu11B6 was 85.1 ± 
5.2% (n = 7) with a radiochemical purity of >99% (n = 
7). The stability of [177Lu]hu11B6 in plasma and PBS 
was 68± 5% (n = 3) and 70% (n=1) at one week, 
respectively. The affinity constant for conjugated 
hu11B6 was not found to be significantly different 
when compared to non-conjugated hu11B6 (p = 0.18) 
(see suppl. information). 
Specific activity and Biodistribution  
Organ-to-blood ratios were largely unaffected by 
specific activity except for at the highest amount of 
antibody (150 µg), which resulted in higher uptake in 
lung, spleen and muscle tissues (Figure 1A). 
Tumor-to-blood ratios (Figure 1B) seem to be lower at 
higher amounts of antibody, possibly due to 
competitive inhibition, however they did not differ 
significantly between the groups (non-parametric 
 
 
Figure 1. A. The Organ-to-blood ratio for 10-150 µg labeled hu11B6 at 72h, uptake in the studied normal organs do not seem to change with increasing antibody amount 
up to 150 µg. B. The Tumor-to-blood ratio for 10-150 µg labeled hu11B6 at 72h, the tumor to blood ratio varies and seem to be lower at higher amounts of antibody, 
possibly because of competitive inhibition, however the variation is not statistically significant (p = 0.07). C. The Biokinetics of 177Lu-hu11B6 (20-30 µg). Tumor uptake 
increased up to 1 w p.i. Generally, normal organs had far less accumulation of the tracer compared to tumor, except for the submandibular glands (as a cross-reaction between 
human hK2 and a species specific kallikrein found in rodent salivary glands). D. Organ-to-blood ratio for 177Lu-hu11B6 versus time derived from data in Figure 1C.  
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Kruskal-Wallis test, p = 0.07). Peak tumor specific 
uptake (29.1 ± 9.1 %IA/g) was noted at 1 w, and 
maximum tumor-to-blood ratio 9.6 ± 6.1 was noted at 
14 days, with blood clearance as the major reason for 
this increase (Figure 1C-D), which corresponds well 
with previously reported results [13, 20]. Uptake of 
[177Lu]hu11B6 was also noted in the submandibular 
glands. This finding is unrelated to humans and has 
previously been reported as a possible cross-reaction 
between 11B6 and a non-specified species-specific 
kallikrein expressed in rodent salivary glands [13, 20]. 
The accumulation in the submandibular glands was 
15 ± 5 %IA/g at one week which can be compared 
with the residual activity in other normal organs at 
between 0.2 -7.0 %IA/g at the same time (Figure 1C). 
Compared to other non-kallikrein expressing organs, 
clearance of [177Lu]hu11B6 was slower in the liver and 
spleen, organs known to degrade full-sized antibodies 
(Figure 1D).  
SPECT/CT 
Representative SPECT/CT images for 4, 7, 9 and 
14 days are displayed in Figure 2A. The specific 
uptake (%IA/g) calculated from the SPECT 
acquisition followed a different trend in xenografts as 
compared to the biodistribution with subtherapeutic 
amounts of activity (compare Figure 1C and Figure 
2B). Instead of peaking at 7-9 d the specific uptake 
continued to increase with time. The difference could 
be explained by the therapeutic absorbed doses 
delivered by the amount of [177Lu]hu11B6 used for 
SPECT imaging. Over time this leads to decrease in 
tumor volume, e.g. the group of mice imaged at 7 and 
14 d, had a tumor size reduction of about 50% within a 
week. This is further supported by the small change in 
%IA for the same group (Figure 2C). The normal 
organs follow a similar trend as compared to the 
biodistribution, except for the submandibular glands 
(compare Figure 1C and Figure 2B). This could be due 
to the difficulty of drawing ROIs over the glands or 
from effects of treatment reducing the specific uptake. 
 
 
Figure 2. SPECT/CT imaging A. Representative maximum intensity projections of SPECT/CT of mice at 4, 7, 9 and 14 days p.i. of 177Lu-hu11B6. B. 
Biokinetics as %IA/g of therapeutic amounts of 177Lu-hu11B6 (20-30 µg) quantified from SPECT data. Quantified data from SPECT/CT imaging of 177Lu-hu11B6 for 
tumor, submandibular gland, liver and heart. The tumor biokinetics for therapeutic amounts of 177Lu-hu11B6 is different from that seen in Figure 1C, the %IA/g continues to 
increase after 7d, probably as an effect of internalization of 177Lu-hu11B6 and tumor shrinkage following therapy. C. Quantified %IA data from SPECT/CT imaging of 
177Lu-hu11B6. Evidently, while the group at nine days had a lower %IA/g it has a higher %IA. This is due to a somewhat larger tumor size in this group. It is probable that the 
high uptake in the xenografts of this group reduces the amount of 177Lu-hu11B6 in other organs. 
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Figure 3. A. Kaplan-Meier survival curve for the therapy and control groups. Square: 177Lu-hu11B6, group A, with a median survival of 19 days. Triangle: 
177Lu-hu11B6, group B, uncensored (all animals), median survival 77 days; Cross: 177Lu-hu11B6, group B, censored with a median survival beyond 120 days; Stars: unlabeled 
hu11B6 median survival 44 days; Circle: 177Lu-non-specific mAb median survival 33 days; Diamond: Vehicle median survival 23 days. B. Hematopoietic toxicity for the 
therapy group NMRI-foxn1nu/foxn1nu. From dosimetry the absorbed dose to bone marrow was estimated to 7.2-8.8 Gy showing a nadir at about 12 days for white blood 
cells and 18 days for red blood cells where after recovery is seen. The absorbed dose to the tumor in this group was estimated to 56-68 Gy. 
 
Therapeutic Efficacy 
During the first 30 days of therapy the dominant 
factor affecting survival was the pre-set tumor size 
endpoint, not treatment toxicity, and survival is 
therefore in general well reflected in the log(RTS) of 
the different groups. Median survival in mice treated 
with an absorbed dose of 48-53 Gy to the tumor (16.3 - 
18.0 MBq of injected activity) was about twice the 
average median survival of the control groups (Figure 
3A). Unfortunately, some subjects had to be 
euthanized prematurely due to non-tumor size 
related health issues (tail necrosis resulting from the 
blood sampling, eye infections and xenograft 
ulceration). These cases were censored to obtain a 
tumor growth relevant read-out of the therapeutic 
effect (Figure 3A). Monitoring of the hematological 
status in [177Lu]hu11B6 treated mice showed a 
temporary decline during the first 12 days. At nadir 
the levels of white blood cells, red blood cells and 
platelets were 1.7± 1.0 109/L, 6.6± 1.2 1012/L and 207± 
68 109/L, respectively (Figure 3B).  
Compared to control groups ([177Lu]IgG1, vehicle 
and non-labeled hu11B6), [177Lu]hu11B6 treated mice 
showed a decrease in tumor volumes or significantly 
reduced growth rates and xenografts given 48-53 Gy 
to the tumor remained indolent between 25-60 days 
(Table 1, Figure 4A and suppl. information Figure S2). 
A single injection of [177Lu]hu11B6, corresponding to 
tumor absorbed doses of 30-38 Gy (10.2 - 12.7 MBq of 
injected activity), 48-53 Gy (16.3 - 18.0 MBq of injected 
activity) and 56-68 Gy (18.9 - 23.1 MBq of injected 
activity) at 25 days, resulted in RTS of 1.5 ± 0.2 (n = 
10), 0.29 ± 0.07 (n = 8) and 0.22 ± 1.17 (n = 9), 
respectively. In corresponding control groups, RTS in 
[177Lu]IgG1, vehicle and non-labeled hu11B6 treated 
groups were 2.4 ± 0.8 (n =8), 2.2 ± 0.4 (n = 10) and 6.6 ± 
0.8 (n = 12), respectively, at 23 days. However, mice 
receiving very high levels of activity (1650 ± 131 
MBq/kg of [177Lu]hu11B6) had to be euthanized at 
day 10−12 p.i. due to poor general condition. The 
administrated activity to this group corresponds to a 
bone marrow absorbed dose of 15-16 Gy, which is 
above the reported maximum tolerable absorbed dose 
to bone marrow in mice [30]. These results were not 
found to be significantly different from previously 
reported data based on 177Lu-labeled non-humanized 
11B6 murine IgG1 and are included in Table 1 and 
Figure 4A for comparison [20].  
Dosimetry, DAR based small-scale dosimetry 
and Immunohistochemistry 
The average total tumor mean absorbed dose 
calculated from biodistribution data was 
approximately 3 Gy/MBq, which is approximately six 
times higher than most normal organs. Importantly, 
the total absorbed dose was only 0.4 Gy/MBq in bone 
marrow, which is about 10 times lower than the 
absorbed dose to the tumor (Table 1, S3 suppl. 
information).  
Analysis of DAR images showed that the mean 
absorbed dose rate increased over the first 14 days of 
the study period (Figure 5A). The small-scale 
dosimetry performed on sections of tumors at 
different time points revealed that there is a 
heterogeneous absorbed dose rate distribution within 
the tumor. As can be seen in Figure 5A, the maximum 
and mean absorbed dose rates differ by as much as a 
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factor of five. This means that a portion of the tumor 
receives much higher absorbed doses. The 
comparisons with the mean absorbed dose rate 
calculated from the biokinetics clearly show great 
variability of absorbed dose rate, findings that could 
not be discovered using a dosimetry based on 
biodistribution data only. An increasing ratio of 
maximum over mean absorbed dose rate over time 
indicated that the activity concentrates into smaller 
areas over the observed period (Figure 5B), which is to 
be attributed to internalization and lysosomal 
degradation of [177Lu]hu11B6 in target cells and a 
decreasing number of vital cells per tissue area. This 
conclusion is further supported by the SPECT data 
(Figure 2B) where retention of [177Lu]hu11B6 as the 
tumor decreases manifests as an increasing specific 
uptake (%IA/g). During the earlier time-points, high 
activity could be noted in stromal tissues representing 
blood activity. 
 
Table 1. The experimental design with amongst others the administered activity (MBq), specific activity (MBq/kg) and tumor and 
bone marrow dosimetry for the [177Lu]hu11B6 therapy study with seven (A-G) groups of animals. Included are data from our previous 
study with the murine 11B6 antibody [18]. The range of tumor volumes at therapy start are presented in table S1 in the supplementary 
data. Administered amount of [177Lu]hu11B6 was 20-30 µg.  
Group n Treatment Administered 
Activity (MBq) 
Specific Activity 
(MBq/kg) 
Weight at 
injection (g) 
Range of 
Administered 
Activity (MBq) 
Range of Specific 
Activity 
(MBq/kg) 
Range of Absorbed 
Dose to tumor** 
(Gy) 
Range of Absorbed 
Dose to bone 
marrow** (Gy) 
BALB/c-foxn1nu/foxn1nu 177Lu-hu11B6 
A 14 177Lu-hu11B6 11.0 ± 0.8 512 ± 85 22 ± 3 10.2 – 12.7 425 - 704 30 – 38 3.8 – 4.9 
B 10 177Lu-hu11B6 17.1 ± 0.5 674± 59 25 ± 3 16.3 – 18.0 610 - 782 48 – 53 6.2 – 6.9  
C 9 177Lu-hu11B6 41.2 ± 1.5 1650 ± 131 25 ± 2 39.5 – 42.3 1413 - 1804 117 – 124 15 – 16 
D 8 177Lu-ns- mAb 18.8 ± 2.2 802 ± 140 24 ± 2 13 – 20.5 550 - 950 - - 
E 12 hu11B6 – -  – - - - 
F 13 Vehicle – -  – - - - 
NMRI-foxn1nu/foxn1nu 177Lu-hu11B6 
G 21 177Lu-hu11B6 20.9 ± 1.3 586 ± 54.3 35.8 ± 2.8 18.9 – 23.1 483 - 670 56 – 68 7.2 – 8.8 
NMRI-foxn1nu/foxn1nu 177Lu-m11B6*** 
H 5 177Lu-m11B6 10.1 ± 1.2 330 ± 25 30.6 ± 3.0 7.83 – 11.5 301 - 372 23 – 34 3.0 – 4.0 
I 6 177Lu-m11B6 19.1 ± 1.4 649 ± 102 30.8 ± 3.0 17.4 – 21.1 512 - 812 51 – 62 6.6 – 8.0 
J 3 177Lu-m11B6 36.2 ± 0.7 1080 ± 68 33.7 ± 2.9 35.2 – 37.0 1000 - 1128 104 – 109 13 – 14 
Values are, when applicable, presented as mean ± SD. * As calculated based on the biodistribution study shown in Figure 1C. and the average organ weights of the BALB/c 
foxn1nu/nu therein. ***Original data published elsewhere, Vilhelmsson Timmermand et al. [18] 
 
 
Figure 4. Linear regression of the logarithm of the relative tumor size (log(RTS) +/- SD). This method was applied for the initial 30 days’ growth and growth delay 
data analysis. A. The log(RTS) over time for all the therapy groups with 177Lu-hu11B6. Also included the data previously presented [18] for the murine antibody 11B6. Both the 
humanized and murine 11B6 shows similar therapeutic efficacy. Even though no tumor decrease in group A is observed, there is a growth delay compared to the controls (E, F, 
D). B. The log(RTS) versus tumor absorbed dose, albeit at different dose rates, for all the therapy groups. As can be seen there is almost a linear correlation showing a similar 
absorbed dose dependent therapeutic efficacy in all groups except in group A. This pattern is recognizable among data from both the humanized, hu11B6 (A, B, G) and the 
previously published murine (H, I) antibody.  
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Figure 5. Absorbed dose and activity and absorbed dose rate distributions in tumor sections compared to histology and Ki-67 staining, 1 – 30 days after 
administration of 177Lu-hu11B6. A. Mean and maximum absorbed dose rate as measured in tumor sections together with mean tumor absorbed dose from macrodosimetry 
calculated for the injected activity of the measured group. B. Absorbed dose rate ratio of Max to Mean. C. From left to right: Representative digital autoradiography images of 
activity uptake individually scaled to %IA/g. The same tissue sections stained with hematoxylin and eosin. Adjacent sections stained for the proliferation marker Ki-67. Finally, the 
distribution of absorbed dose rate at the moment of sacrifice, collectively scaled to mGy/h. From top to bottom 4, 9, 14 and 30 days after injection. 
 
Histological scoring of tumor tissue showed 
similar homogenous staining of AR at all timepoints 
(Table 2). Staining for proliferation (Ki-67) and 
senescence (SA-β-gal activity) appears to be 
negatively correlated with low staining for Ki-67 at 
9-14 days and high staining for SA-β-gal activity at 14 
days (Table 2). Representative images of the SA-β-gal 
activity stainings can be found in the suppl. material. 
Although some variability was observed during the 
time course, an overall correlation was noted between 
increasing activity uptake and decreasing Ki-67 
staining intensity (nadir at 9 and 14 days p.i.) 
suggesting that [177Lu]hu11B6 inhibits cellular 
proliferation (Table 2 and Table 3). In addition, at later 
time-points higher activity was noted in fibrotic areas 
surrounded by regions of low Ki-67 staining. No 
activity uptake was found in necrotic tumor areas. 
(Figure 5C). Analysis of the mean AR staining 
intensity for each of the tissue section’s cells ranged 
from 134 to 194 (arbitrary units). The results show that 
the AR expression level remained roughly constant 
over time up until two weeks but then at 30 days the 
remaining viable cells had significantly greater AR 
expression intensity (p = 0.017) compared to that of 
the pooled data from the 4-14 day time points and the 
controls (Figure 6A-B).  
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Figure 6. AR intensity analysis. A. Scatterplot with standard deviation and mean showing androgen receptor stain intensity which was pooled for controls (Ctrl) and 4-14 d 
and displayed separately for 30 d after initiation of radioimmunotherapy. Each point represents the intensity mean for a tumor section taken from a single animal. The AR intensity 
is significantly higher at 30 d indicating a AR flair phenomenon as result of DNA repair machinery. B. Representative tumor sections from which the data was derived. Top row 
shows the AR expression stain levels as a function of time. Bottom row shows the masks used to select AR expressing cells for AR expression analysis. 
 
Table 2. Ki-67, AR immunohistochemistry and SA-β-gal 
activity staining. The intensity of the sections was graded 
independently by two different observers on a scale from nothing 
(-) to the highest intensity (+++). The average intensity is 
presented in the table. 
Days p.i. Average staining intensity 
 Ki-67 AR SA-β-gal activity 
4d  ++ +++ ++ 
9d  + +++ ++ 
14d  + +++ +++ 
30d ++ +++ ++ 
Control +++ +++ + 
 
Table 3. Correlation between nuclei stained for 
proliferation (Ki-67) and DAR image activity and 
absorbed dose rate 
 Spearman correlation coefficient 
Time p.i. (d) Ki-67 staining vs. 
activity 
Ki-67 staining vs. absorbed-dose rate at the time 
of sacrifice 
4  -0.548† -0.523† 
9  -0.750† -0.672† 
14  -0.409 -0.379 
30  -0.343 -0.346 
†p < 0.01 
 
Discussion 
Disabling the AR-signaling pathway has been 
the central pillar of PCa treatment since the seminal 
studies of Huggins and Hodges more than a 
half-century ago [31]. The major downfall with 
managing CRPC using this treatment strategy is the 
rapid development of resistance. Despite combining 
high affinity AR-blockers with steroid pathway 
synthesis inhibitors, the increased median survival in 
this patient group is only a couple of months. An 
alternative treatment path is to target potent cytotoxic 
agents to the sites of AR-driven PCa. We have 
addressed this unmet need for sustainable treatment 
effects by developing a radioimmunotherapeutic 
platform targeting hK2, a tightly AR-regulated 
prostate kallikrein. hK2 is a well characterized 
protease, with 80% amino acid homology to PSA. 
Other prostate-targeting agents lack specificity to 
prostate-derived tissue with significant off-target 
accumulation. Therefore, in vivo targeting of hK2 can 
be a significant improvement over PSMA, which has a 
high expression in non-target organs and in 
radiosensitive tissues such as the kidney. This issue is 
also prevalent among other targeting strategies, such 
as bombesin/gastrin-released peptide receptor 
(GRP-R) and prostate stem cell antigen (PSCA). 
Off-target accumulation limits the utility of cytotoxic 
radiolabeled small molecules and antibodies in 
treating prostate cancer and calls attention to the need 
for better engineered biologic delivery molecules. 
Furthermore, the clinical impact of AR-directed 
therapy on PSMA expression is poorly understood. 
PSMA expression has been shown to increase with AR 
inhibition [32] but also to decrease following long 
term ADT with an uneven metastatic expression (45% 
of metastatic lesions are PSMA-positive) [33]. 
Interestingly, in enzalutamide-resistant disease with 
glucocorticoid receptor cross-activated AR pathway, 
KLK2 (hK2) expression, but not KLK3 (PSA) or FOLH1 
(PSMA), is restored [34], suggesting hK2 as an optimal 
target for imaging and therapy.  
Our previous reports, based on preclinical 
studies in advanced GEM models of prostate 
adenocarcinoma and metastatic disease, have shown 
that intravenously introduced radio- or fluorescently 
labeled 11B6 achieve uptake, internalization, and 
lysosomal degradation in hK2 expressing cells 
through an FcRn-mediated mechanism [13]. Cellular 
internalization provides permanent deposition of 
radionuclides in the cell. In this study we labeled 
hu11B6 with177Lu, generating [177Lu]hu11B6, which 
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emits beta--particles at the site of the tumor. 
Compared to short-range alpha-emitters (such as 
Actinium-225, Bismuth-213 and Astatine-211), the 
long-ranging betas from [177Lu]hu11B6 result in a 
crossfire effect. This could potentially be lethal to 
surrounding heterogeneous cell populations with 
lower AR and lower target expression. Thus even 
nearby cancer cells that do not internalize hu11B6 will 
be irradiated. The capability of hu11B6 to deliver 
payloads close to the nucleus, as compared to cell 
membrane binding targeting, is of high importance 
for the therapeutic efficacy when using alpha particle 
emitters. Following internalization of [177Lu]hu11B6 to 
the nucleus, a contribution from short ranged 
conversion electrons to the resulting absorbed dose 
can also be expected. 177Lu also emits two prominent 
easily imaged medium energy photons (113 and 208 
keV at 6.8 and 10.4% abundance, respectively) which 
have been shown to produce images with a 
quantitative accuracy of better than 5-6% [35, 36] and 
can therefore be used in a theranostic approach to hK2 
targeted RIT. Further, in a clinical setting, it is possible 
that some patients might not benefit from the use of 
this radioimmuoconjugate due to high serum levels of 
free hK2. However, this could then be determined 
with a simple blood test already conducted today. 
Evaluating the therapeutic efficacy of 
[177Lu]hu11B6 revealed that a single injection resulted 
in good therapeutic response with acceptable overall 
toxicity. The results are in line with our previously 
reported results based on a murine version of 11B6 
[20]. Interestingly, the relationship between 
therapeutic efficacy, measured as log(RTS) and 
absorbed dose to the tumor, is similar for most 
administrated activities both in the present study and 
in adapted data from our previous report (Figure 4B). 
In clinical practice, potent and promising agents (such 
as Radium-223) are administered on a per-weight 
basis, without accounting for patient-specific disease 
characteristics or the absorbed dose needed at lesions 
to eradicate disease. Accounting for a dose-effect 
relationship in targeted radionuclide therapy is 
debated, although clinical studies have confirmed 
dose-effect relationships, they are not very strong and 
there are few preclinical studies that can demonstrate 
clear relationships [37, 38]. This could in part be due 
to the lack of accurate preclinical dosimetry models 
[37]. In our study, the administrated activity and 
absorbed dose versus log change in tumor volume 
(log(RTS)) generally demonstrated a clear and 
repeatable dose-effect relationship between tumor 
response and relapse (Figure 3A and Figure 4A-B). 
However, tumor specific uptake (%IA/g) acquired 
from SPECT data deviates from that seen at 14 d when 
using subtherapeutic amounts of activity (compare 
Figure 1C with 2B). This is because the volume of the 
xenograft decreases as an effect of therapy which 
means that the true absorbed dose to the remaining 
tumor probably is higher than the one calculated 
based on subtherapeutic activity biodistribution. A 
similar effect has been shown clinically in lymphoma 
patients [39]. However, at the same time the specific 
uptake in heart and liver is similar with therapeutic 
activities. The decrease in tumor volume and increase 
over time in specific uptake, as observed with SPECT 
imaging, confirms the functionality with respect to 
internalization, retention and therapeutic efficacy of 
[177Lu]hu11B6. Our findings therefore further support 
a SPECT-based theranostic approach where 
pre-therapy treatment planning can predict normal 
organ toxicity and intratherapeutic dosimetry can 
predict the therapeutic efficacy. This highlights the 
need for robust and accurate dosimetry models in 
preclinical evaluation of RIT compounds for solid 
tumor treatment, thereby overcoming a significant 
deficiency in the existing practice of 
radiopharmaceutical therapy agent translation and 
application [40]. 
The heterogeneous absorbed dose distribution 
following RIT implies that some malignant cells, not 
directly targeted, could escape treatment. Or, 
conversely, that there are areas within the tumor with 
relatively high absorbed dose compared to the mean. 
In this study, some absorbed doses reach values of 
several hundred Gy, which could be an additional 
explanation for good therapeutic results. We therefore 
investigated the microdistribution of [177Lu]hu11B6 
and found a dose-effect relationship between the 
absorbed dose rate and the proliferation (Ki-67) in 
different areas of the xenograft as well as an, over 
time, increasing max-to-mean activity ratio between 
different parts of the tumor (Table 3, Figure 5B). 
However, though some tumor regions showed 
varying degrees of response, histological staining and 
absorbed dose rate distribution over time (Figure 5C) 
together with the drastic decrease in tumor volume 
reveals that large parts of the initially targeted tumor 
are efficiently treated. The SPECT data on tumor 
specific uptake and the data on changing 
max-to-mean activity ratio support one another and 
confirms the retention of the radionuclide in the 
tumor over time. The retention of the radionuclide 
and decreasing tumor volume is likely the reason for 
retained absorbed dose rates within the tumor up to 
14 days after injection (Figure 5C). Therapeutic effect 
in an area of the tumor could thus lead to higher 
absorbed doses in other parts of the tumor due to the 
crossfire effect. The results show that both macro- and 
small-scale dosimetry approaches and methods are 
useful to fully understand the therapeutic response. 
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Uptake of [177Lu]hu11B6 over time could be 
further stimulated by an increase in the AR axis 
activity as an effect of therapy. The change in mean 
AR staining intensity at 30 days points to a selection 
mechanism or some pathway upregulation that 
results in a net per-cell increase of AR protein level 
following irradiation. As suggested in previous 
studies, this could be due to a general increase in 
DNA repair mechanisms dependent on AR 
upregulation as a response to irradiation. This 
phenomenon would then manifest itself later with 
low LET beta-particles, post 14 days as opposed to 
earlier reported 6-14 days for high LET alpha particles 
[14]. Or it could be explained by the clonal selection of 
cell lineages that use AR upregulation as a mechanism 
of resistance. In our case this cell population would 
then become dominant enough at 30 days to be 
detected as an increase in mean AR staining intensity. 
This theory could further explain the difference seen 
between low LET beta-particles in this study and 
previously studied high LET alpha particles. 
Irradiation with low LET beta-particles results 
predominantly in so called sub-lethal damage e.g. 
SSB, as compared to high LET alpha particles which 
mainly give rise to DSB. High LET irradiation has also 
been shown to induce more apoptosis compared to 
low LET irradiation [41] and to a faster cell death 
progression due to more severe damage. Two weeks 
into therapy we see large areas of cells stained for 
SA-β-gal activity (Table 2) and low proliferation, 
which together indicates senescence [42, 43]. A 
senescent cellular state is an indefinite cell cycle arrest 
as a consequence of irreparable sub-lethal damage e.g. 
DNA damage or oxidative stress and the inability to 
enter apoptosis [42]. Large numbers of senescent cells 
in LNCaP xenografts after therapy with low LET 
beta-particles could mask a clonal selection of lineages 
with high AR expression by influencing the result of 
measured mean AR status so that this phenomenon 
appears to be delayed when compared to therapy 
with high LET alpha-particles. The AR flair 
phenomenon could therefore be the result of cells in 
general responding to DNA damage by upregulation 
of DNA repair pathways that involve the AR or from 
subpopulations of cells that do so.  
A potential therapeutic strategy, encouraged by 
the enhanced AR expression several weeks after onset 
of therapy, is to perform serial administration of 
radiolabeled hu11B6. Our findings that AR protein 
levels are increasing after [177Lu]hu11B6 therapy 
(Figure 6), support earlier findings of increasing levels 
of AR mRNA following [225Ac]hu11B6 therapy [14] 
and points at a persistent and high AR signaling in 
remaining cells following irradiation and hk2 targeted 
RIT. This means that the response to treatment, 
instead of just conveying resistance, could lead to 
continuously high uptake of hu11B6. However, it 
remains to be further investigated how high and low 
LET particle emissions, as well as different absorbed 
dose rates, differ in their influence on this 
radiobiological phenomenon. However, besides serial 
administration, the parallel use of different 
radionuclides with different LET is therefore also of 
interest for further development. The combination of 
therapy with both beta emitters and alpha emitters, 
the later with high linear energy transfer and high 
relative biological effect, as well as external beam 
radiation therapy could be an interesting expansion of 
the hK2 targeting RIT hu11B6 platform. 
Conclusion 
This preclinical study with 177Lu-radiolabeled 
immuno-targeting of hK2 demonstrated good 
therapeutic efficacy with one of the treated groups 
showing a large reduction in tumor volume together 
with reversible myelotoxicity. The tumor response 
was dependent on administered activity and 
delivered absorbed dose, as evaluated on both macro 
and small-scale dosimetric levels. These results, 
together with the findings of persistent hK2 and 
increasing AR levels support the use of SPECT 
imaging approaches for dosimetry and therapy 
evaluation. Interestingly, hu11B6 radiolabeled with 
177-lutetium, a low LET beta-emitter, appeared to 
induce a similar AR flair phenomenon, albeit at a later 
time point, in remaining prostate cancer cells as was 
previously seen after [225Ac]hu11B6 treatment and 
irradiation with a 137Cs source. In view of previously 
published data, this study suggests that this could be 
due to either a general DNA repair mechanism or 
because of clonal lineage selection. The phenomenon 
could potentially be used in therapeutic strategies 
with serial [177Lu]hu11B6 or 
parallel/co-administration of [177Lu]hu11B6 and 
[225Ac]hu11B6.  
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